HACKENSACK, N.J.--(BUSINESS WIRE)--ReGen Biologics (OTC: RGBO) (“ReGen”) reported the first surgeon training course in support of U.S. launch for the Menaflex™ collagen meniscus implant. The focus of the course was to “train the trainers” who will be instrumental in educating U.S. surgeons interested in the Company’s recently cleared device.
